Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Clinical Cancer Research

• Publication date

  2017-03-06

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-16-2655PMID 28264871PMCID PMC5540763
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Different definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic review

  2016cited by this paper
• Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1.

  2015cited by this paper
• POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer

  2015cited by this paper
• The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints

  2015cited by this paper
• PD-1 blockade in tumors with mismatch repair deficiency.

  2015cited by this paper
• Advances in the Management of Recurrent Endometrial Cancer

  2015cited by this paper
• PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

  2015cited by this paper
• Polymerase ɛ (POLE) mutations in endometrial cancer: Clinical outcomes and implications for Lynch syndrome testing

  2015cited by this paper
• Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.

  2015cited by this paper
• Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis.

  2014cited by this paper
• Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy

  2014cited by this paper
• Role of microsatellite instability-low as a diagnostic biomarker of Lynch syndrome in colorectal cancer.

  2014cited by this paper
• Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis.

  2014cited by this paper
• Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

  2014cited by this paper
• Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer.

  2014influential reference
• Subsets of microsatellite-unstable colorectal cancers exhibit discordance between the CpG island methylator phenotype and MLH1 methylation status

  2013cited by this paper
• Status and Significance of CpG Island Methylator Phenotype in Endometrial Cancer

  2012cited by this paper
• A phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.

  2011cited by this paper
• Status and Significance of CpG Island Methylator Phenotype in Endometrial Cancer

  2011cited by this paper
• The Role of the CpG Island Methylator Phenotype in Colorectal Cancer Prognosis Depends on Microsatellite Instability Screening Status

  2010cited by this paper
• Treatment options for advanced endometrial carcinoma.

  2010cited by this paper
• Systemic therapy for recurrent endometrial cancer: a review of North American trials

  2009cited by this paper
• Prospective evaluation of DNA mismatch repair protein expression in primary endometrial cancer.

  2009cited by this paper
• Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support

  2009cited by this paper
• Epitope landscape in breast and colorectal cancer.

  2008cited by this paper
• CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer

  2006cited by this paper
• Tumour‐infiltrating lymphocytes in colorectal cancer with microsatellite instability are activated and cytotoxic

  2004cited by this paper
• Frequent HOXA11 and THBS2 promoter methylation, and a methylator phenotype in endometrial adenocarcinoma.

  2003cited by this paper
• Cancer,Facts and Figures about.

  year unknowncited by this paper

• Hereditary Endometrial Cancer: Lynch Syndrome, Mismatch Repair Deficiency, and Emerging Genetic Predispositions—A Comprehensive Review with Clinical and Laboratory Guidelines

  2026influential citation
• Organ-sparing strategies in patients with MSI/dMMR tumors including Lynch syndrome: Current state of the art and future perspectives for clinical decision-making.

  2025cites this paper
• Universal Screening for Lynch Syndrome and molecular classification of patients with endometrial cancer.

  2025cites this paper
• Nivolumab and ipilimumab combination treatment in advanced dMMR/MSI-H non-colorectal cancers: Results from a phase II trial

  2025cites this paper
• TIME for Endometrial Cancer: Advancements and Challenges in Therapeutic Targets for the Endometrial Cancer Tumor Immune Microenvironment.

  2025cites this paper
• [Characteristics of the immune microenvironment of endometrial cancer depending on the MMR status of the tumor].

  2025cites this paper
• Extracellular granzyme B and K are associated with endometriosis severity in infertile women.

  2025cites this paper
• Traditional and New Views on MSI-H/dMMR Endometrial Cancer

  2025influential citation
• Immune landscape and TAM density in endometrial cancer: implications for immune checkpoint inhibitors efficacy

  2025cites this paper
• A phase 2 trial of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability (NCT02899793): Updated survival and response analyses.

  2025cites this paper
• Deep learning to identify aggressive endometrial cancer and predict tumor mutational burden from histopathology slide

  2025cites this paper
• Are all mismatch repair deficient endometrial cancers created equal? A large, retrospective, tertiary center experience.

  2025cites this paper
• Detection of Mismatch Repair Deficiency in Endometrial Cancer: Assessment of IHC, Fragment Length Analysis, and Amplicon Sequencing Based MSI Testing

  2024cites this paper
• PD-L1 Expression and Immune Infiltration Across Molecular Subtypes of Endometrial Cancer: An Integrative-Analysis of Molecular Classification and Immune Subtypes.

  2024cites this paper
• Expression Analysis of FANCD2 in Endometrial Carcinoma

  2024cites this paper
• Advances in Immunotherapy for Endometrial Cancer: Insights into MMR Status and Tumor Microenvironment

  2024cites this paper
• Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).

  2024cites this paper
• Prognostic significance of negative lymph node count in microsatellite instability-high colorectal cancer

  2024cites this paper
• The evolving role of immune checkpoint inhibitors in cervical and endometrial cancer

  2024cites this paper
• Unveiling pembrolizumab effectiveness in diverse subtypes of MSI-high endometrial cancers

  2024cites this paper
• The M2 macrophages infiltration of sebaceous tumors is linked to the aggressiveness of tumors but not to the mismatch repair pathway

  2023cites this paper
• A comprehensive analysis of immunotherapy in advanced endometrial cancer (Review).

  2023cites this paper
• Immune checkpoint inhibitors: here to stay

  2023cites this paper
• Radiogenomics for predicting microsatellite instability status and PD-L1 expression with machine learning in endometrial cancers: A multicenter study

  2023cites this paper
• Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial)

  2023cites this paper
• The role and participation of immune cells in the endometrial tumor microenvironment.

  2023cites this paper
• T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapy

  2023cites this paper
• Tumor Immune Microenvironment in Gynecologic Cancers

  2023cites this paper
• Molecular subtypes of endometrial cancer: Implications for adjuvant treatment strategies

  2023cites this paper
• Advances in immunotherapy for gynecological malignancies.

  2023cites this paper
• Context-dependent environmental associations with endometrial cancer histotype and genotype

  2023cites this paper
• A review of basic to clinical targeted therapy and immunotherapy in uterine serous cancer

  2023cites this paper
• Pathologic, Immunologic, and Clinical Analysis of the Microsatellite Instability Phenotype in Endometrial Carcinoma.

  2023cites this paper
• Exceptional Response to Pembrolizumab for Treatment of Metastatic Chemorefractory Endometrial Carcinoma in a Patient with Lynch Syndrome: A Case Report

  2023cites this paper
• Tumor Microenvironment CD8 T and Treg Cells–related Genes Signature Distinguishes Distinct Prognosis and Targeted Therapies Response in Endometrial Cancer

  2023cites this paper
• Could Inhibiting the DNA Damage Repair Checkpoint Rescue Immune-Checkpoint-Inhibitor-Resistant Endometrial Cancer?

  2023cites this paper
• Mechanisms driving the immunoregulatory function of cancer cells

  2023cites this paper
• Immune Environment and Immunotherapy in Endometrial Carcinoma and Cervical Tumors

  2023cites this paper
• Highly Sensitive Microsatellite Instability and Immunohistochemistry Assessment in Endometrial Aspirates as a Tool for Cancer Risk Individualization in Lynch Syndrome.

  2023cites this paper
• Immunotherapy in endometrial cancer

  2023cites this paper
• Deciphering comprehensive features of tumor microenvironment controlled by chromatin regulators to predict prognosis and guide therapies in uterine corpus endometrial carcinoma

  2023cites this paper
• Tumor immune microenvironment in endometrial cancer of different molecular subtypes: evidence from a retrospective observational study

  2022cites this paper
• Regulatory patterns analysis of transcription factor binding site clustered regions and identification of key genes in endometrial cancer

  2022cites this paper
• Immune checkpoint inhibitors for recurrent endometrial cancer

  2022influential citation
• Discordant prognosis of mismatch repair deficiency in colorectal and endometrial cancer reflects variation in antitumour immune response and immune escape

  2022cites this paper
• Immunosuppressive tumor microenvironment in Uterine Serous Carcinoma via CCL7 signal with myeloid-derived suppressor cells.

  2022cites this paper
• How Immunotherapy Modified the Therapeutic Scenario of Endometrial Cancer: A Systematic Review

  2022cites this paper
• A novel risk prediction model of pyroptosis-related genes for the prognosis and immunotherapy response of endometrial cancer.

  2022cites this paper
• Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study

  2022cites this paper
• Facts and hopes in immunotherapy of endometrial cancer.

  2022cites this paper
• Recent progress in the use of pharmacotherapy for endometrial cancer

  2022cites this paper
• Novel approaches for treatment of endometrial carcinoma.

  2022cites this paper
• Integrated pan-cancer analysis of CSMD2 as a potential prognostic, diagnostic, and immune biomarker

  2022influential citation
• Lynch Syndrome: From Carcinogenesis to Prevention Interventions

  2022cites this paper
• Presence of regulatory T-cells in endometrial cancer predicts poorer overall survival and promotes progression of tumor cells

  2022cites this paper
• Pembrolizumab as a single agent for patients with MSI-H advanced endometrial carcinoma

  2022cites this paper
• Knockdown of RAD51AP1 suppressed cell proliferation and invasion in esophageal squamous cell carcinoma

  2022cites this paper
• Effect of Tertiary Lymphoid Structures on Prognosis of Patients with Hepatocellular Carcinoma and Preliminary Exploration of Its Formation Mechanism

  2022cites this paper
• The impact of single agent PD-1 or PD-L1 inhibition on advanced endometrial cancers: meta-analysis

  2022cites this paper
• Identification of tumour antigens and immune subtypes in the development of an anti‐cancer vaccine for endometrial carcinoma

  2022cites this paper
• Identification of an immune-related risk signature and nomogram predicting the overall survival in patients with endometrial cancer

  2021cites this paper
• Mismatch repair and clinical response to immune checkpoint inhibitors in endometrial cancer

  2021cites this paper
• A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability

  2021influential citation
• Proceedings of the Expert Council “Treatment of inoperable endometrial cancer in Russia: issues that have not yet been addressed”

  2021cites this paper
• Материалы заседания экспертного совета «Нерешенные вопросы в лечении неоперабельного рака эндометрия в России»

  2021cites this paper
• DNA methylation-based signature of CD8+ tumor-infiltrating lymphocytes enables evaluation of immune response and prognosis in colorectal cancer

  2021cites this paper
• Endometrial cancer in Lynch syndrome

  2021cites this paper
• Development and validation of m6A regulators’ prognostic significance for endometrial cancer

  2021cites this paper
• Endometrial Carcinoma: Immune Microenvironment and Emerging Treatments in Immuno-Oncology

  2021influential citation
• Immunotherapy in endometrial cancer: rationale, practice and perspectives

  2021influential citation
• Predictive and Prognostic Value of Microsatellite Instability in Gynecologic Cancer (Endometrial and Ovarian)

  2021cites this paper
• A durable response to pembrolizumab in a patient with uterine serous carcinoma and Lynch syndrome due to the MSH6 germline mutation.

  2021cites this paper
• Additional Value of PET/CT-Based Radiomics to Metabolic Parameters in Diagnosing Lynch Syndrome and Predicting PD1 Expression in Endometrial Carcinoma

  2021cites this paper
• Tumour microenvironment and PD-L1 expression in endometrial carcinoma

  2021cites this paper
• A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793).

  2021cites this paper
• Immune checkpoint inhibitors in endometrial cancer.

  2021cites this paper
• PD-L 1 expression in endometrial carcinoma cells and intratumoral immune cells : 1 differences across histological and TCGA-based molecular subgroups 2

  2021influential citation
• Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer

  2021cites this paper
• MLH1/PMS2-deficient Endometrial Carcinomas in a Universally Screened Population: MLH1 Hypermethylation and Germline Mutation Status

  2021cites this paper
• Reconstruction of Immune Microenvironment and Signaling Pathways in Endometrioid Endometrial Adenocarcinoma During Formation of Lymphovascular Space Involvement and Lymph Node Metastasis

  2020cites this paper
• The immunologic tumor microenvironment in endometrioid endometrial cancer in the morphomolecular context: mutual correlations and prognostic impact depending on molecular alterations

  2020cites this paper
• RNF183 Is a Prognostic Biomarker and Correlates With Tumor Purity, Immune Infiltrates in Uterine Corpus Endometrial Carcinoma

  2020cites this paper
• Machine learning-based prediction of microsatellite instability and high tumor mutation burden from contrast-enhanced computed tomography in endometrial cancers

  2020cites this paper
• Immune disorder in endometrial cancer: Immunosuppressive microenvironment, mechanisms of immune evasion and immunotherapy

  2020cites this paper
• Implications of Hereditary Origin on the Immune Phenotype of Mismatch Repair-Deficient Cancers: Systematic Literature Review

  2020cites this paper
• Immune Checkpoint Inhibitors: A Promising Choice for Endometrial Cancer Patients?

  2020cites this paper
• Microsatellite instability and mismatch repair protein expressions in lymphocyte‐predominant breast cancer

  2020cites this paper
• ACE2 correlated with immune infiltration serves as a prognostic biomarker in endometrial carcinoma and renal papillary cell carcinoma: implication for COVID-19

  2020cites this paper
• Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma

  2020cites this paper
• Circulating Transcripts and Biomarkers in Uterine Tumors: Is There a Predictive Role?

  2020cites this paper
• Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer

  2020cites this paper
• A global immune gene expression signature for human cancers

  2019cites this paper
• Microsatellite instability in endometrial cancer: New purpose for an old test

  2019cites this paper
• Endocrinology of obese and nonobese endometrial cancer patients: is there role of tumor molecular-biological type?

  2019cites this paper
• Variable Expression of MSH6 in Endometrial Carcinomas With Intact Mismatch Repair and With MLH1 Loss Due to MLH1 Methylation

  2019cites this paper
• Immunological, molecular and therapeutic mechanisms in endometrial cancer

  2019cites this paper
• PD-L1 Expression in Endometrial Carcinoma Cells and Intratumoral Immune Cells

  2019cites this paper
• High endothelial venules are associated with microsatellite instability, hereditary background and immune evasion in colorectal cancer

  2019cites this paper
• Immune response characterization of endometrial cancer

  2019cites this paper
• Molecular Genetics of Endometrial Carcinoma.

  2019cites this paper